Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed squamous cell carcinoma or adenocarcinoma of the thoracic esophagus~  * Carcinoma of the gastroesophageal junction (i.e., Siewert staging system type I disease) allowed~* Locally advanced disease~  * Obstructive tumors are considered locally advanced disease~ * Meets 1 of the following staging criteria:~    * T3, N0 disease~   * T1-3, N1 disease~   * T4, N0-1 disease~* Resectable disease~  * No T4 (unequivocal organ involvement) disease that cannot be resected with curative intent~* No airway infiltration in case of tumors of the upper third of the thoracic esophagus~* No cervical esophageal carcinoma~* No distant metastasis, including stage M1a (celiac node involvement) by fine-needle aspiration or biopsy~PATIENT CHARACTERISTICS:~* WHO performance status 0-1~* Creatinine clearance \> 60 mL/min~* Bilirubin normal~* Alkaline phosphatase ≤ 2.5 times upper limit of normal (ULN)~* AST ≤ 1.5 times ULN~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 12 months after completion of study treatment~* No other malignancy within the past 5 years except nonmelanomatous skin cancer or adequately treated in situ cervical cancer~* No severe or uncontrolled cardiovascular disease including, but not limited to, any of the following:~  * New York Heart Association class III or IV congestive heart failure~ * Unstable angina pectoris~ * Myocardial infarction within the past 3 months~ * Significant arrhythmias~* No psychiatric disorder that would preclude study compliance~* No active uncontrolled infection~* No serious underlying medical condition that, in the opinion of the investigator, would interfere with study participation (e.g., uncontrolled diabetes mellitus or active autoimmune disease)~* No peripheral neuropathy \> grade 1~* No contraindications to corticosteroids~* No known hypersensitivity to any component of the study drugs~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy~* No prior radiotherapy to the chest~* No participation in another clinical trial within the past 30 days~* No other concurrent experimental drugs or anticancer therapy~* No concurrent drugs contraindicated for use with the study drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).